Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Orchestra BioMed Holdings (OBIO – Research Report), LENZ Therapeutics (LENZ – Research Report) and Amgen (AMGN – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orchestra BioMed Holdings (OBIO)
BTIG analyst Marie Thibault maintained a Hold rating on Orchestra BioMed Holdings yesterday. The company’s shares closed last Tuesday at $4.08, close to its 52-week low of $3.75.
According to TipRanks.com, Thibault has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Orchestra BioMed Holdings is a Strong Buy with an average price target of $13.40, a 229.2% upside from current levels. In a report issued on January 30, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $4.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
LENZ Therapeutics (LENZ)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on LENZ Therapeutics today and set a price target of $35.00. The company’s shares closed last Tuesday at $15.53, close to its 52-week low of $14.42.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
Currently, the analyst consensus on LENZ Therapeutics is a Strong Buy with an average price target of $53.83, which is a 229.0% upside from current levels. In a report issued on January 29, William Blair also assigned a Buy rating to the stock with a $58.00 price target.
Amgen (AMGN)
In a report released today, Luca Issi from RBC Capital reiterated a Buy rating on Amgen, with a price target of $360.00. The company’s shares closed last Tuesday at $338.59, close to its 52-week high of $346.85.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $358.81, representing a 5.1% upside. In a report issued on January 22, DBS also maintained a Buy rating on the stock with a $400.00 price target.
